US2017239205A1PendingUtilityA1
Glycogen or polysaccharide storage disease treatment method
Est. expiryJul 2, 2024(expired)· nominal 20-yr term from priority
Inventors:Charles R. Roe
A61P 3/00A61K 9/0095A61K 38/47A61K 31/23C12Y 302/0102A61K 31/22A23L 33/16A61K 31/19A23L 33/175A23L 33/12A23K 20/158A23L 33/10A61K 31/20A23L 33/115A23K 50/80A23V 2002/00A23K 50/10A23K 50/75A61K 31/202A23K 20/174A61K 9/0053A61K 31/225A23L 2/52
64
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A method for treating glycogen storage disease by administering an effective amount of a composition that includes ketogenic odd carbon fatty acids that ameliorate the symptoms of these diseases.
Claims
exact text as granted — not AI-modified1 - 100 . (canceled)
101 . A method of treating a fatty acid oxidation disorder (FOD) in a subject in need thereof, wherein the method comprises administering to the subject a composition comprising an active agent, wherein the active agent consists essentially of a triheptanoin, and wherein the composition has an acid value of 0.1 or less mg KOH per gram and a hydroxyl value of 2.8 or less mg KOH per gram.
102 . The method of claim 101 , wherein the composition is administered in a range of 1 to 4 grams of triheptanoin per kilogram body weight per day.
103 . The method of claim 101 , wherein the composition is administered in a range of 0.1 to 2 grams of triheptanoin per kilogram body weight per day.
104 . The method of claim 101 , wherein the composition is in a dosage unit, wherein the dosage unit comprises at least 15 grams of the triheptanoin.
105 . The method of claim 104 , wherein the dosage unit comprises 15 to 75 grams of the triheptanoin.
106 . The method of claim 101 , wherein the composition is provided in an amount that provides 15% to 40% of the daily dietary calories of the subject.
107 . The method of claim 101 , wherein the composition is provided in an amount that provides 20% to 35% of the daily dietary calories of the subject.
108 . The method of claim 101 , wherein the composition is provided in an amount that provides 25% to 35% of the daily dietary calories of the subject.
109 . The method of claim 101 , wherein the composition is provided as a nutritional supplement.
110 . The method of claim 101 , wherein the composition is provided as a dietary formulation.
111 . The method of claim 101 , wherein the composition is a pharmaceutical composition.
112 . The method of claim 101 , wherein the composition is administered parenterally.
113 . The method of claim 101 , wherein the composition is administered enterally.
114 . The method of claim 101 , wherein the composition is administered orally.
115 . The method of claim 101 , wherein the FOD is selected from carnitine palmitoyl transferase I (CPT I) deficiency, carnitine-acylcarnitine translocase (CACT) deficiency, carnitine palmitoyl transferase I (CPT II) deficiency, very long chain acyl-CoA dehydrogenase (VLCAD) deficiency, trifunctional protein (TFP) deficiency, long chain acyl 3-hydroxy CoA dehydrogenase (LCHAD) deficiency and short chain acyl CoA dehydrogenase (SCAD) deficiency.
116 . The method of claim 114 , wherein the FOD is CPT II deficiency.
117 . The method of claim 114 , wherein the FOD is VLCAD deficiency.
118 . The method of claim 114 , wherein the FOD is LCHAD deficiency.
119 . The method of claim 114 , wherein the FOD is TFP deficiency.
120 . The method of claim 114 , wherein the FOD is CACT deficiency.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.